Bruce N. Jacobs, Chief Financial Officer at Kymera Therapeutics, Inc. (KYMR), sold 30,000 shares at $52.13 ($1.6M) on 2022-01-12, disclosed to the SEC on 2022-01-14.
Open-market sale of $1.6M KYMR by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $51.21 | 6,427 | $329K | 21.2% |
| 2 | $51.21 | 6,427 | $329K | 21.2% |
| 3 | $52.13 | 7,151 | $373K | 24.0% |
| 4 | $52.13 | 7,151 | $373K | 24.0% |
| 5 | $53.27 | 1,422 | $76K | 4.9% |
| 6 | $53.27 | 1,422 |
| $76K |
| 4.9% |
| Total | $51.84 avg | 30,000 | $1.6M | 100% |
| Filing → |
| KYMR | SELL | 2025-09-17 | $4.0M | — | Filing → |
| KYMR | SELL | 2025-03-03 | $389K | — | Filing → |
| KYMR | SELL | 2024-03-04 | $318K | — | Filing → |